# Daniela Barraco

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/846460/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 32 papers | 844 citations | 643344 15 h-index | 563245 28 g-index |
| 32 all docs | 32 docs citations | 32 times ranked | 1431 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients. Cancer Medicine, 2019, 8, 4089-4092. | 1.3 | 16 |
| 2 | Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project. Haematologica, 2018, 103, e392-e394. | 1.7 | 31 |
| 3 | Monocytosis is a powerful and independent predictor of inferior survival in primary myelofibrosis. British Journal of Haematology, 2018, 183, 835-838. | 1.2 | 32 |
| 4 | Cytogenetic findings in <scp>WHO</scp>â€defined polycythaemia vera and their prognostic relevance. British Journal of Haematology, 2018, 182, 437-440. | 1.2 | 22 |
| 5 | Post-ET and Post-PV Myelofibrosis: Updates on a Distinct Prognosis from Primary Myelofibrosis. Current Hematologic Malignancy Reports, 2018, 13, 173-182. | 1.2 | 19 |
| 6 | Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia. Leukemia Research, 2018, 69, 100-102. | 0.4 | 13 |
| 7 | Momelotinib therapy for myelofibrosis: a 7-year follow-up. Blood Cancer Journal, 2018, 8, 29. | 2.8 | 49 |
| 8 | Prefibrotic versus overtly fibrotic primary myelofibrosis: clinical, cytogenetic, molecular and prognostic comparisons. British Journal of Haematology, 2018, 182, 594-597. | 1.2 | 31 |
| 9 | Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project. Blood Cancer Journal, 2018, 8, 89. | 2.8 | 13 |
| 10 | The prognostic relevance of serum lactate dehydrogenase and mild bone marrow reticulin fibrosis in essential thrombocythemia. American Journal of Hematology, 2017, 92, 454-459. | 2.0 | 12 |
| 11 | Monocytosis in polycythemia vera: Clinical and molecular correlates. American Journal of Hematology, 2017, 92, 640-645. | 2.0 | 40 |
| 12 | Targeted next generation sequencing and identification of risk factors in <scp>W</scp>orld <scp>H</scp>ealth <scp>O</scp>rganization defined atypical chronic myeloid leukemia. American Journal of Hematology, 2017, 92, 542-548. | 2.0 | 64 |
| 13 | Gender and survival in essential thrombocythemia: A twoâ€center study of 1,494 patients. American Journal of Hematology, 2017, 92, 1193-1197. | 2.0 | 27 |
| 14 | DNMT3A mutations are associated with inferior overall and leukemiaâ€free survival in chronic myelomonocytic leukemia. American Journal of Hematology, 2017, 92, 56-61. | 2.0 | 60 |
| 15 | Spectrum of autoimmune diseases and systemic inflammatory syndromes in patients with chronic myelomonocytic leukemia. Leukemia and Lymphoma, 2017, 58, 1488-1493. | 0.6 | 47 |
| 16 | Targeted deep sequencing in polycythemia vera and essential thrombocythemia. Blood Advances, 2016, 1, 21-30. | 2.5 | 243 |
| 17 | Next generation sequencing of myeloid neoplasms with eosinophilia harboring the FIP1L1â€PDGFRA mutation. American Journal of Hematology, 2016, 91, E10-1. | 2.0 | 20 |
| 18 | Calreticulin variant stratified driver mutational status and prognosis in essential thrombocythemia. American Journal of Hematology, 2016, 91, 503-506. | 2.0 | 47 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Momelotinib Therapy in Myelofibrosis: 6-Years Follow-up Data on Safety, Efficacy and the Impact of Mutations on Overall and Relapse-Free Survival. Blood, 2016, 128, 1123-1123. | 0.6 | 4 |
| 20 | Marked Elevation of Serum Lactate Dehydrogenase (LDH) in Primary Myelofibrosis: Clinical and Prognostic Correlates. Blood, 2016, 128, 3113-3113. | 0.6 | 17 |
| 21 | Abnormal Karyotype and Prognosis in Polycythemia Vera: A Single Center Experience in 239 Informative Cases. Blood, 2016, 128, 3115-3115. | 0.6 | 1 |
| 22 | Prefibrotic Versus Overtly Fibrotic Primary Myelofibrosis: Clinical, Cytogenetic, Molecular and Prognostic Comparisons. Blood, 2016, 128, 4247-4247. | 0.6 | 2 |
| 23 | U2AF1 Mutation Variants and Their Phenotypic and Prognostic Relevance in Primary Myelofibrosis. Blood, 2016, 128, 4248-4248. | 0.6 | 1 |
| 24 | Monocytosis Is a Powerful and Independent Predictor of Shortened Overall and Leukemia-Free Survival in Primary Myelofibrosis. Blood, 2016, 128, 4249-4249. | 0.6 | 3 |
| 25 | Risk Factors for Arterial Versus Venous Thrombosis in Polycythemia Vera: Single Center Experience in 587 Patients. Blood, 2016, 128, 948-948. | 0.6 | 6 |
| 26 | Prognostic Impact of Bone Marrow Fibrosis in Polycythemia Vera: Validation of the IWG-MRT Study and Additional Observations. Blood, 2016, 128, 3129-3129. | 0.6 | 0 |
| 27 | Monocytosis in Polycythemia Vera: Clinical and Molecular Correlates. Blood, 2016, 128, 4259-4259. | 0.6 | 0 |
| 28 | Spectrum of Concomitant and Subsequently Diagnosed Second Malignancies in Patients with Chronic Myelomonocytic Leukemia. Blood, 2016, 128, 1989-1989. | 0.6 | 0 |
| 29 | Identification of Serum Lactate Dehydrogenase (LDH) As an Independent Prognostic Biomarker in Polycythemia Vera. Blood, 2016, 128, 3111-3111. | 0.6 | 1 |
| 30 | The Prognostic Relevance of Serum Lactate Dehydrogenase and Mild Reticulin Fibrosis in Essential Thrombocythemia. Blood, 2016, 128, 3120-3120. | 0.6 | 0 |
| 31 | Clinical factors predictive of myelofibrotic evolution in patients with polycythemia vera. Annals of Hematology, 2015, 94, 873-874. | 0.8 | 9 |
| 32 | Targeted Next-Generation Sequencing in Polycythemia Vera and Essential Thrombocythemia. Blood, 2015, 126, 354-354. | 0.6 | 14 |